Table 1.
Ongoing clinical trials with compounds targeting S1P receptors.
| Drug | S1P receptor activity | Target disease | Clinical trial phase | NCT number | Sponsor |
|---|---|---|---|---|---|
| Siponimod (BAF312) | S1P1,5 | SPMS | III-Active | 01665144 | Novartis Pharmaceuticals |
| RRMS | II-Active | 01185821 | |||
| Polymyositis | II-Recruiting | 01801917 | |||
| Dermatomyositis | II-Completed | 02029274 | |||
| SPMS | III-Active | 02330965 | NIH-NIAID | ||
| Fingolimod (FTY720) | S1P1,3,4,5 | RRMS | Approved | Novartis Pharmaceuticals | |
| Primary progressive MS | III-Completed | 00731692 | |||
| Stroke | II-Recruiting | 02002390 | Tianjin Medical University | ||
| Ponesimod (ACT128800) | S1P1,3,5 | RRMS | II-Active | 01093326 | Actelion |
| Chronic graft vs. host disease | II-Not yet recruiting | 02461134 | |||
| Plaque psoriasis | II-Completed | 01208090 | |||
| Relapsing MS | III-Recruiting | 02425644 | |||
| Ozanimod (RPC1063) | S1P1,5 | Relapsing MS | III-Active | 02294058 | Celgene |
| Ulcerative colitis | III-Recruiting | 02435992 | |||
| Crohn's disease | III-Recruiting | 02531113 | |||
| Ceralifimod (ONO-4641) | S1P1,5 | RRMS | II Extension-terminated | 01226745 | EMD Serono |
| Cenerimod (ACT-334441) | S1P1 | SLE | II-Recruiting | 02472795 | Actelion |
| Amiselimod (MT-1303) | S1P1 | RRMS | II-Completed | 01890655 | Mitsubishi Tanabe Pharma Corporation |
| Plaque psoriasis | II-Completed | 01987843 | |||
| SLE | I-Recruiting | 02307643 | |||
| Inflammatory bowel disease | I-Completed | 01666327 | |||
| Crohn's disease | II-Recruiting | 02378688 | |||
| LX3305 (LX2931) | S1P lyase inhibitor | RA | II-Completed | 00903383 | Lexicon Pharmaceuticals |
| AKP11 | S1P1 | Psoriasis | II-Recruiting | Unavailable | Akaal Pharma |
| KRP-203 | S1P1 | Subacute cutaneous lupus erythematous | II-Completed | 01294774 | Novartis Pharmaceuticals |
| Ulcerative colitis | II-Completed | 01375179 | |||
| ADP334 | S1P1 | Ulcerative colitis | II-Recruiting | Unavailable | Arena Pharmaceuticals |
| GSK2018682 | S1P1 | RRMS | I-Completed | 01466322 | GlaxoSmithKline |